drugset / Trial / NCT02560363

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

NCT02560363

Phase 1 Withdrawn AstraZeneca
RandomizedCrossoverOpen-labelBasic science

Summary

This is an open-label, randomized, cross over single oral dose study to compare the pharmacokinetics of different formulations of AZD9977 in Part A and the influence of food in Part B in healthy male subjects

Timeline

Start
2015-11
Primary completion
2016-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject balcinrenone Small molecule 120 mg Oral

Indications

No indication recorded.